Last reviewed · How we verify
NCT04215666
Diagnostic Criteria of ARDS at High Altitudes in Western China
trial in ARDS in 3,000 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Affiliated Hospital of Qinghai University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 1 December 2019 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Conditions studied
- ARDS — all drugs for ARDS →
Sponsor
Affiliated Hospital of Qinghai University
Who can join
18 and older, any sex, with ARDS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The severity of ARDS in high altitude areas was classified according to the Berlin standard high altitude area Oxygenation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04215666
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ARDS
Currently open trials in the same condition.
- NCT07362537 — Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS · NA · recruiting
- NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
- NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
- NCT07370610 — Electrical Impedance Tomography-Based Dynamic Ventilation-Perfusion Functional Phenotype Trajectory in Acute Respiratory · active not recruiting
- NCT06647784 — Lateral Positioning and Prone Positioning in ARDS Patients · NA · recruiting
Other Affiliated Hospital of Qinghai University trials
Trials by the same sponsor.
- NCT07208305 — Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting · Phase 3 · recruiting
- NCT06772935 — Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer · NA · recruiting
- NCT06602167 — Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot S · NA · recruiting
- NCT05094310 — Genetic Predictors of Response to Acupuncture for Cancer-related Fatigue Among Breast Cancer Patients After Chemotherapy · NA · unknown
- NCT05275569 — Personalized Electroacupuncture Treatment for Chemotherapy-induced Nausea and Vomiting in Breast Cancer (PET) · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04215666 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Qinghai University
- Last refreshed: 2 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04215666.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing